Open AccessCOLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients WithBRAFV600–Mutant Melanoma
Author(s) -
Reinhard Dummer,
Keith T. Flaherty,
Caroline Robert,
Ana Arance,
Jan Willem B. de Groot,
Claus Garbe,
Helen Gogas,
Ralf Gutzmer,
Ivana Krajsová,
Gabriella Liszkay,
Carmen Loquai,
Mario Mandalà,
Dirk Schadendorf,
Naoya Yamazaki,
Alessandra di Pietro,
Jean Cantey-Kiser,
Adrian Edwards,
Paolo A. Ascierto
Publication year - 2022
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.21.02659
Subject(s) - vemurafenib , medicine , tolerability , melanoma , metastatic melanoma , adverse effect , cancer research
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom